Leap Therapeutics, Inc. Banner Image

Leap Therapeutics, Inc. has reached its limit for free report views

Work for Leap Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Leap Therapeutics, Inc.

  • Ticker LPTX
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Leap Therapeutics, Inc. Logo Image
  • 11-50 Employees
  • Based in Cambridge, Massachusetts
Leap Therapeutics (Nasdaq:LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a collaborationMore with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Leap Therapeutics, Inc.

Most Recent Annual Report

Leap Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Leap Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports